Search research articles
Contact Us
Filters
Showing results (61-70 of 101) with videos related to
Page
of 11
Sort By:
Cardiovascular Drugs and Therapy
|
March 19, 2011
Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides
Christie M Ballantyne, Peter H Jones, Maureen T Kelly, et al.
Clinical Therapeutics
|
November 9, 2004
Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial
Peter H Jones, Donald B Hunninghake, Keith C Ferdinand, et al.
Journal of Clinical Lipidology
|
June 1, 2019
Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
Don P Wilson, Terry A Jacobson, Peter H Jones, et al.
American Heart Journal
|
October 12, 2010
Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia
Peter H Jones, Anne C Goldberg, Howard R Knapp, et al.
Journal of Clinical Lipidology
|
September 6, 2022
Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
Don P Wilson, Terry A Jacobson, Peter H Jones, et al.
Clinical Chemistry
|
June 25, 2005
Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system
Mine Y Liu, Antonios M Xydakis, Ron C Hoogeveen, et al.
Atherosclerosis
|
September 6, 2011
Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia
Ariel Brautbar, Daniel Covarrubias, John Belmont, et al.
Atherosclerosis
|
January 24, 2007
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)
James M McKenney, Peter H Jones, Harold E Bays, et al.
Atherosclerosis
|
February 10, 2009
Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels
Seiko Otokozawa, Masumi Ai, Thomas Van Himbergen, et al.
The American Journal of Cardiology
|
January 25, 2011
Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation
Nuntakorn Thongtang, Masumi Ai, Seiko Otokozawa, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 101) with videos related to
Sort By:
Page
of 11
Cardiovascular Drugs and Therapy
|
March 19, 2011
Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides
Christie M Ballantyne, Peter H Jones, Maureen T Kelly, et al.
Clinical Therapeutics
|
November 9, 2004
Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial
Peter H Jones, Donald B Hunninghake, Keith C Ferdinand, et al.
Journal of Clinical Lipidology
|
June 1, 2019
Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
Don P Wilson, Terry A Jacobson, Peter H Jones, et al.
American Heart Journal
|
October 12, 2010
Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia
Peter H Jones, Anne C Goldberg, Howard R Knapp, et al.
Journal of Clinical Lipidology
|
September 6, 2022
Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
Don P Wilson, Terry A Jacobson, Peter H Jones, et al.
Clinical Chemistry
|
June 25, 2005
Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system
Mine Y Liu, Antonios M Xydakis, Ron C Hoogeveen, et al.
Atherosclerosis
|
September 6, 2011
Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia
Ariel Brautbar, Daniel Covarrubias, John Belmont, et al.
Atherosclerosis
|
January 24, 2007
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)
James M McKenney, Peter H Jones, Harold E Bays, et al.
Atherosclerosis
|
February 10, 2009
Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels
Seiko Otokozawa, Masumi Ai, Thomas Van Himbergen, et al.
The American Journal of Cardiology
|
January 25, 2011
Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation
Nuntakorn Thongtang, Masumi Ai, Seiko Otokozawa, et al.
Page
of 11